Humana (NYSE:HUM) Downgraded by Zacks Research to “Hold”

Humana (NYSE:HUM) was downgraded by stock analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research note issued on Tuesday,Zacks.com reports. Zacks Research also issued estimates for Humana’s Q1 2027 earnings at $9.04 EPS.

A number of other analysts also recently issued reports on the stock. Royal Bank Of Canada lifted their price objective on shares of Humana from $246.00 to $415.00 and gave the stock a “sector perform” rating in a report on Thursday, July 9th. Jefferies Financial Group upgraded Humana from a “buy” rating to a “buy” rating in a research report on Wednesday, May 20th. Lake Street Capital began coverage on Humana in a research note on Thursday, July 30th. They set a “buy” rating on the stock. Guggenheim upped their target price on Humana from $269.00 to $471.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Finally, Evercore raised Humana from an “in-line” rating to an “outperform” rating and set a $480.00 price target for the company in a research note on Wednesday, July 29th. Fourteen investment analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $395.22.

Humana Stock Performance

Shares of HUM opened at $388.86 on Tuesday. Humana has a 1 year low of $163.11 and a 1 year high of $428.88. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.74 and a quick ratio of 1.74. The stock’s fifty day moving average price is $380.56 and its two-hundred day moving average price is $274.05. The firm has a market cap of $46.69 billion, a PE ratio of 36.79, a PEG ratio of 2.13 and a beta of 0.72.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, July 29th. The insurance provider reported $7.61 earnings per share for the quarter, topping the consensus estimate of $7.27 by $0.34. Humana had a return on equity of 11.20% and a net margin of 0.88%.The company had revenue of $40.89 billion during the quarter, compared to the consensus estimate of $40.58 billion. During the same quarter in the prior year, the company earned $6.27 EPS. The firm’s quarterly revenue was up 26.2% compared to the same quarter last year. On average, equities research analysts forecast that Humana will post 9.09 EPS for the current year.

Institutional Investors Weigh In On Humana

Several large investors have recently added to or reduced their stakes in HUM. Montag A & Associates Inc. increased its position in shares of Humana by 1,880.0% during the fourth quarter. Montag A & Associates Inc. now owns 99 shares of the insurance provider’s stock worth $25,000 after acquiring an additional 94 shares during the period. Johnson Financial Group Inc. bought a new stake in shares of Humana during the second quarter valued at approximately $26,000. Fideuram Asset Management Ireland dac purchased a new stake in shares of Humana in the fourth quarter valued at approximately $27,000. Trust Co. of Vermont purchased a new stake in shares of Humana in the second quarter valued at approximately $28,000. Finally, Reflection Asset Management bought a new position in Humana in the fourth quarter worth approximately $29,000. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.